Sino Biological Inc
SZSE:301047
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Sino Biological Inc
EPS (Diluted)
Sino Biological Inc
EPS (Diluted) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | EPS (Diluted) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
Sino Biological Inc
SZSE:301047
|
EPS (Diluted)
¥1
|
CAGR 3-Years
-20%
|
CAGR 5-Years
-33%
|
CAGR 10-Years
N/A
|
|
|
Beigene Ltd
HKEX:6160
|
EPS (Diluted)
¥0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Innovent Biologics Inc
HKEX:1801
|
EPS (Diluted)
¥0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
RemeGen Co Ltd
SSE:688331
|
EPS (Diluted)
¥1
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Akeso Inc
HKEX:9926
|
EPS (Diluted)
-¥1
|
CAGR 3-Years
5%
|
CAGR 5-Years
6%
|
CAGR 10-Years
N/A
|
|
|
S
|
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd
HKEX:6990
|
EPS (Diluted)
-¥1
|
CAGR 3-Years
16%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Sino Biological Inc
Glance View
Sino Biological Inc. emerged as a pivotal player in the life sciences sphere from its inception, carving a niche through its extensive portfolio of biological reagents, particularly recombinant proteins and antibodies. This Beijing-headquartered company swiftly gained acclaim by developing high-quality, cost-effective products that cater to the needs of researchers, pharmaceutical companies, and biotechnology firms worldwide. Its expansive catalog, boasting thousands of products, is meticulously curated to support research and development in areas such as immunology, cancer research, and infectious diseases. Sino Biological’s facility, equipped with state-of-the-art technology, combines automation with expert human oversight to ensure precision in production, fundamentally driving its reputation for reliability and innovation. At the heart of Sino Biological’s business model lies a commitment to accelerating the pace of biomedical research through its comprehensive suite of products and services. The company generates revenue by not only selling its own products but also by offering custom services, including protein production, antibody development, and assay development, tailored to meet specific client needs. By employing a business strategy that emphasizes collaboration and tailored solutions, Sino Biological successfully fosters long-term partnerships with its clients. This approach not only fortifies its foothold in the industry but also ensures a steady income stream as it plays a vital role in facilitating breakthroughs in medical research and development globally.
See Also
What is Sino Biological Inc's EPS (Diluted)?
EPS (Diluted)
1.2
CNY
Based on the financial report for Dec 31, 2025, Sino Biological Inc's EPS (Diluted) amounts to 1.2 CNY.
What is Sino Biological Inc's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 5Y
-33%
Over the last year, the EPS (Diluted) growth was 27%. The average annual EPS (Diluted) growth rates for Sino Biological Inc have been -20% over the past three years , -33% over the past five years .